NRx Pharmaceuticals (NASDAQ:NRXP) today reported its financial results and operational milestones for the full year ended December 31, 2025, highlighting a successful restructuring of its balance sheet and the transition into a revenue-generating entity.
Achieve Life Sciences (NASDAQ:ACHV) today reported its financial results for the fourth quarter and full year ended December 31, 2025, alongside a series of transformative regulatory and operational updates for its lead smoking cessation candidate, cytisinicline.
Karyopharm Therapeutics (NASDAQ:KPTI) today announced topline results from its global Phase 3 SENTRY clinical trial (n=353) evaluating the XPO1 inhibitor selinexor in combination with ruxolitinib (Jakafi®) for the frontline treatment of patients with myelofibrosis.
BioNTech (NASDAQ:BNTX) announced today its comprehensive participation in the European Lung Cancer Congress (ELCC) 2026, where the company will present updated data across its diversified lung cancer portfolio.
Radiopharm Theranostics (NASDAQ:RADX) today released a highly encouraging second interim data update from its ongoing U.S. Phase 2b clinical trial evaluating RAD 101, a novel FASN-targeting small-molecule imaging agent.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Dupixent (dupilumab) for the treatment of adults with moderate-to-severe bullous pemphigoid (BP) whose disease is not adequately controlled by existing therapies.
Pharming Group (NASDAQ:PHAR) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Joenja (leniolisib) as the first targeted treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Abivax (NASDAQ:ABVX) today announced its full-year 2025 financial results and provided a comprehensive corporate update, underscored by a significantly strengthened capital structure and steady clinical progress.
Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) today announced topline results from the Phase 3 VALOR study evaluating their 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405.
Avalo Therapeutics (NASDAQ:AVTX), a clinical-stage biotechnology company focused on developing interleukin-1β (IL-1β)-targeting therapies for immune-mediated inflammatory diseases, reported its financial results for the full year ended December 31, 2025.
Arbutus Biopharma (NASDAQ:ABUS) today reported a landmark set of financial and clinical results for the fourth quarter and full year ended December 31, 2025.
BioLineRx (NASDAQ:BLRX) today announced its audited financial results for the full year ended December 31, 2025, detailing a period of significant fiscal discipline and pipeline maturation.
